A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer

This first-in-human, open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of PRT13722, an oral KAT6A protein degrader, in adults with locally advanced or metastatic Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. PRT13722 will be evaluated as monotherapy and in combination with fulvestrant, abemaciclib plus fulvestrant, or imlunestrant to determine recommended dose(s) for expansion (RDE) and evaluate preliminary clinical activity.

Trial Details

NCT ID
NCT07905001
Phase
PHASE1
Sponsor
Prelude Therapeutics Incorporated
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • PRT13722
  • Fulvestrant
  • Abemaciclib
  • Imlunestrant
Locations (sample)
  • Tamarac, Florida, United States|26.21286,-80.24977
  • Maumee, Ohio, United States|41.56283,-83.65382
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requireme…
  • histological or cytological diagnosis of locally advanced or metastatic HR-positive/HER2-negative breast cancer
  • Disease progression following prior standard therapy and eligible for the assigned study cohort
  • Measurable or evaluable disease per RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →